Differential effects of lovastatin on the trafficking of endogenous and lipoprotein-derived cholesterol in human monocyte-derived macrophages

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 18, Issue 8, 1998, Pages 1322-1329

  Cignarella, Andrea ^a   Brennhausen, Beate ^a   Von Eckardstein, Arnold ^a   Assmann, Gerd ^a   Cullen, Paul ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

ApoE; Cholesterol esterification; Human macrophages; Lovastatin

Indexed keywords

MEVINOLIN;

ACETYLATION; ARTICLE; ATHEROGENESIS; DRUG EFFECT; ENZYME INHIBITION; ESTERIFICATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HYDROLYSIS; LIPOPROTEIN METABOLISM; MACROPHAGE ACTIVATION; PRIORITY JOURNAL; RECEPTOR UPREGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSLUMINAL CORONARY ANGIOPLASTY;

EID: 0031815798     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.18.8.1322     Document Type: Article

References (14)

1. Grundy SM. HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. N Engl J Med. 1988;319:24-33.
2. Treasure CB, Klein JL, Weintraub WS, Talley JD, Stillabower ME, Kosinski AS, Zhang J, Boccuzzi SJ, Cedarholm JC, Alexander RW. Beneficial effects of cholesterol lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med. 1995;332:481-487.
3. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
4. Brown G, Albers JJ, Fisher LD, Schaefer SM, Lin JT, Kaplan C, Zhao XQ, Bisson BD, Fitzpatrick VF, Dodge HT. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 1990;323:1289-1298.
5. Alaupovic P, Knightgibson C, Mack WJ, Kramsch DM, Hodis HN, Blankenhom DH. Effect of lovastatin on apoA-containing and apoB-containing lipoprotein families: a report from the Mevacor Atherosclerosis Regression Study. Circulation. 1992;86:743-743.
6. Blankenhom DH, Azen SP, Kramsch DM, Mack WJ, Cashin-Hemphill L, Hodis HN, Deboer LWV, Mahrer PR, Masteller MJ, Vailas LI, Alaupovic P, Hirsch LJ. Coronary angiographie changes with lovastatin therapy: the Monitored Atherosclerosis Regression Study (MARS). Ann Intern Med. 1993;119:969-976.
7. Alaupovic P, Hodis HN, Knightgibson C, Mack WJ, Labree L, Cashin-Hemphill L, Corder CN, Kramsch DM, Blankenhom DH. Effects of lovastatin on apoA- and apoB-containing lipoproteins: families in a subpopulation of patients participating in the Monitored Atherosclerosis Regression Study (MARS). Arterioscler Thromb. 1994;14:1906-1914.
8. Waters D, Higginson L, Gladstone P, Kimball B, Lemay M, Boccuzzi SJ, Lesperance J, Francetich M, Martin H, Flintoft V, Belanger F, Desjardins C, Cloutier MJ, Laurier J, Chagnon S, Furberg C, Leiter L, Theroux P, Davies R, Hudgin R, Krip G, Darbyson K, Granja D, Conroy B, Cook T, Hirsch LJ, Greguski R, Till A, Hwang I, Bugianesi C. Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography: the Canadian Coronary Atherosclerosis Intervention Trial. Circulation. 1994;89:959-968.
9. Sahni R, Maniet AR, Voci G, Banka VD. Prevention of restenosis by lovastatin after successful coronary angioplasty. Am Heart J. 1991;121:1600-1608.
10. Corsini A, Mazzotti M, Raiteri M, Soma MR, Gabbiani G, Fumagalli R, Paoletti R. Relationship between mevalonate pathway and arterial myocyte proliferation: in vitro studies with inhibitors of HMG-CoA reductase. Atherosclerosis. 1993;101:117-125.
11. Soma MR, Donetti E, Parolini C, Mazzini G, Ferrari C, Fumagalli R, Paoletti R. HMG-CoA reductase inhibitors: in vivo effects on carotid intimal thickening in normocholesterolemic rabbits. Arterioscler Thromb. 1993;13:571-578.
12. Han ZY, Wyche JH. Lovastatin induces apoptosis in a metastatic ovarian tumor-cell line. Cell Death Diff. 1996;3:223-228.
13. Sindermann J, Weigel K, Muller JG, Breithardt G. Lovastatin causes down-regulation of cyclin-dependent kinase-2, up-regulation of tyrosine phosphorylation, and is capable of inducing apoptosis in human, bovine and rat vascular smooth-muscle cells. Circulation. 1996;94(suppl I):I-639-I-640.
14. Kempen HJM, Vermeer M, Dewit E, Havekes LM. Vastatins inhibit cholesterol ester accumulation in human monocyte-derived macrophages. Arterioscler Thromb. 1991;11:146-153.